ANI Pharmaceuticals vs Harrow
ANIP and HROW side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ANIP and HROW compare
ANI Pharmaceuticals is the larger company, worth 1.5 times as much as Harrow ($1.6B against $1.1B).
ANI Pharmaceuticals grew revenue faster over the last twelve months (25.9% versus 21.3% for Harrow).
ANI Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of 11.2% compared with −9.4% at Harrow.
ANI Pharmaceuticals scores higher on the StockData Score (15 against 6 for Harrow), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ANIP | HROW |
|---|---|---|
| Size and price | ||
| Market cap | $1.6B | $1.1B |
| Share price | $71.44 | $30.12 |
| Change, 1 year | −18.1% | −21.6% |
| Change, 5 years | 64.1% | 179% |
| Beta (5Y) | 0.61 | 1.37 |
| Employees | 970 | 373 |
| StockData Score | ||
| Total score | 15 (better) | 6 |
| Valuation score | 5 (better) | 0 |
| Growth score | 2 | 3 (better) |
| Performance score | 4 (better) | 2 |
| Health score | 4 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 13.5× | – |
| P/S | 1.6× (better) | 3.7× |
| P/B | 2.6× (better) | 38.7× |
| EV/EBITDA | 6.1× | – |
| P/FCF | 8.0× | – |
| FCF yield | 12.5% (better) | −1.8% |
| Fair value | $153.69 | – |
| Margin of safety | 53.5% | – |
| Growth | ||
| Revenue growth (TTM) | 25.9% (better) | 21.3% |
| Revenue growth, 5Y average | 33.5% | 41.0% (better) |
| Net income growth (TTM) | 188% | – |
| EPS growth (TTM) | 225% | – |
| Profitability | ||
| Gross margin | 61.1% | 73.5% (better) |
| Operating margin | 16.0% (better) | −2.0% |
| Net margin | 11.2% (better) | −9.4% |
| FCF margin | 19.7% (better) | −6.7% |
| Return on equity | 20.4% (better) | −74.8% |
| Return on invested capital | 23.0% (better) | −2.1% |
| Financial health | ||
| Debt / equity | 0.47 (better) | 10.03 |
| Net debt / EBITDA | −0.49 | – |
| Interest coverage | 5.4× (better) | −0.3× |
| Current ratio | 2.75 (better) | 2.29 |
| Altman Z-score | 2.57 (better) | 2.07 |
| Piotroski F-score | 7 (better) | 5 |
| Dividends and buybacks | ||
| Payout ratio | 0.00% | – |
| Buyback yield | 1.2% | – |
| Shareholder yield | 1.2% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 100% | 57.4% |
| Held by insiders | 12.3% | 14.2% |
| Insider net buying, 12 months | −$13.6M | −$9.2M (better) |
| Short interest, % of float | 17.8% | 22.1% |
Go deeper
- ANIP stock overview
- ANIP income statement
- ANIP valuation and score
- HROW stock overview
- HROW income statement
- HROW valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.